Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1958 3
1959 1
1960 1
1961 1
1962 4
1963 2
1964 14
1965 5
1966 4
1967 4
1968 6
1969 3
1970 2
1971 2
1972 2
1974 5
1975 5
1976 2
1977 4
1978 5
1979 2
1980 6
1981 8
1982 10
1983 10
1984 16
1985 14
1986 10
1987 22
1988 22
1989 17
1990 32
1991 21
1992 33
1993 35
1994 37
1995 37
1996 39
1997 48
1998 42
1999 54
2000 52
2001 58
2002 84
2003 62
2004 88
2005 78
2006 68
2007 82
2008 97
2009 73
2010 80
2011 86
2012 84
2013 73
2014 91
2015 83
2016 93
2017 83
2018 80
2019 80
2020 111
2021 117
2022 121
2023 121
2024 88
2025 79

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,545 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: harada n. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma.
Mizumura K, Gon Y, Harada N, Yamada S, Fukuda A, Ozoe R, Maruoka S, Abe S, Takahashi K, Tanaka A, Sagara H, Akamatsu T, Shirai T, Masaki K, Fukunaga K, Kobayashi K, Nagase H, Miyahara N, Kanehiro A, Kitamura N, Sugihara N, Kumasawa F, Terada-Hirashima J, Hojo M, Chibana K, Tagaya E. Mizumura K, et al. Among authors: harada n. Allergol Int. 2025 Jan;74(1):144-155. doi: 10.1016/j.alit.2024.08.005. Epub 2024 Sep 13. Allergol Int. 2025. PMID: 39277433 Free article.
Physiology and clinical applications of GIP.
Yamane S, Harada N, Inagaki N. Yamane S, et al. Among authors: harada n. Endocr J. 2025 Jul 1;72(7):751-764. doi: 10.1507/endocrj.EJ25-0087. Epub 2025 Apr 3. Endocr J. 2025. PMID: 40175127 Free PMC article. Review.
Elevated Serum Growth Differentiation Factor 15 Levels as a Potential Biomarker of the Efficacy of Imeglimin in Individuals With Type 2 Diabetes Mellitus: An Exploratory Study.
Wada N, Murakami T, Fauzi M, Sakaki K, Oshima S, Shimada Y, Asai K, Oshima A, Nomura S, Joo E, Mori M, Fujiwara R, Shide K, Wada K, Yabe D, Inagaki N, Harada N. Wada N, et al. Among authors: harada n. J Clin Med Res. 2024 Oct;16(10):503-508. doi: 10.14740/jocmr6031. Epub 2024 Oct 30. J Clin Med Res. 2024. PMID: 39544328 Free PMC article.
Refractory phenotype of Aspergillus-sensitized asthma with bronchiectasis and allergic bronchopulmonary aspergillosis.
Nomura N, Matsumoto H, Asano K, Hayashi Y, Yokoyama A, Nishimura Y, Hashimoto N, Sakagami T, Fukunaga K, Hizawa N, Yamasaki A, Nagase H, Hattori N, Kondo M, Harada N, Sugiura H, Miki M, Kimura T, Toyoshima M, Matsuno O, Koh H, Kita T, Tomioka H, Tomii K, Ohnishi H, Takata S, Tobino K, Imokawa S, Sunadome H, Nagasaki T, Oguma T, Tanabe N, Hirai T; BEXAS study. Nomura N, et al. Among authors: harada n. J Allergy Clin Immunol Glob. 2024 Nov 1;4(1):100364. doi: 10.1016/j.jacig.2024.100364. eCollection 2025 Feb. J Allergy Clin Immunol Glob. 2024. PMID: 39659740 Free PMC article.
Role of GIP receptor signaling in β-cell survival.
Harada N, Inagaki N. Harada N, et al. Diabetol Int. 2017 Mar 30;8(2):137-138. doi: 10.1007/s13340-017-0317-z. eCollection 2017 Jun. Diabetol Int. 2017. PMID: 30603316 Free PMC article. No abstract available.
2,545 results